Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

>2 years >20 visits Confirmation phase (III)Cost Reimbursement Investigational Medicines InjectionHematologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Vyvgart

Vyvgart is a medicine used to treat generalized myasthenia gravis, a condition that causes muscle weakness.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Efgartigimod Alfa

Efgartigimod alfa is a substance that lowers harmful antibodies to treat autoimmune conditions such as generalized myasthenia gravis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Argx-113

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Kepler Universitaetsklinikum GmbH

Hämatologie und Onkologie

Linz, Austria

Ordensklinikum Linz GmbH

(Hämato)onkologie und Hämostaseologie

Linz, Austria

Klinikum Wels-Grieskirchen GmbH

Department of Internal Medicine IV (Oncology, Hematology and Nephrology)

Wels, Austria

Sponsor: Argenx

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.